Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
Onco-Innovations (OTCQB:ONNVF) has entered into a services agreement with Redwood AI to advance the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound technology. The collaboration aims to enhance the company's drug development capabilities through AI-driven chemistry tools.
The partnership will leverage Redwood AI's expertise in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the PNKP technology. The proprietary compound targets solid tumors by increasing sensitivity to radiation and DNA-damaging chemotherapies. This strategic collaboration is designed to support Onco's progression toward First-in-Human studies by improving scalability, safety, and discovery precision.
Onco-Innovations (OTCQB:ONNVF) ha stipulato un accordo di servizi con Redwood AI per avanzare nello sviluppo della sua tecnologia esclusivamente concessa in licenza Polynucleotide Kinase Phosphatase (PNKP). La collaborazione mira a potenziare le capacità di sviluppo farmaceutico dell'azienda attraverso strumenti chimici basati sull'intelligenza artificiale.
La partnership sfrutterà l'esperienza di Redwood AI nella valutazione della sintesi, cheminformatica e previsione della tossicità specifica per organo applicata alla tecnologia PNKP. Il composto proprietario agisce contro i tumori solidi aumentando la sensibilità alla radioterapia e alle chemioterapie che danneggiano il DNA. Questa collaborazione strategica è pensata per supportare Onco nel progresso verso gli studi First-in-Human migliorando la scalabilità, la sicurezza e la precisione nella scoperta.
Onco-Innovations (OTCQB:ONNVF) ha firmado un acuerdo de servicios con Redwood AI para avanzar en el desarrollo de su tecnología de compuestos Polynucleotide Kinase Phosphatase (PNKP) con licencia exclusiva. La colaboración busca mejorar las capacidades de desarrollo de fármacos de la empresa mediante herramientas químicas impulsadas por inteligencia artificial.
La asociación aprovechará la experiencia de Redwood AI en la evaluación de síntesis, quimioinformática y predicción de toxicidad específica por órgano para la tecnología PNKP. El compuesto patentado está dirigido a tumores sólidos aumentando la sensibilidad a la radiación y quimioterapias que dañan el ADN. Esta colaboración estratégica está diseñada para apoyar el avance de Onco hacia los estudios First-in-Human mejorando la escalabilidad, seguridad y precisión en el descubrimiento.
Onco-Innovations (OTCQB:ONNVF)는 Redwood AI와 독점 라이선스된 Polynucleotide Kinase Phosphatase (PNKP) 화합물 기술 개발을 촉진하기 위한 서비스 계약을 체결했습니다. 이번 협력은 AI 기반 화학 도구를 통해 회사의 신약 개발 역량을 강화하는 것을 목표로 합니다.
이번 파트너십은 PNKP 기술에 대해 합성 평가, 화학정보학, 장기별 독성 예측 분야에서 Redwood AI의 전문성을 활용합니다. 이 독점 화합물은 방사선 및 DNA 손상 화학요법에 대한 민감도를 높여 고형암을 표적으로 합니다. 이 전략적 협력은 확장성, 안전성 및 발견 정확성을 향상시켜 Onco의 First-in-Human 연구 진전을 지원하기 위해 설계되었습니다.
Onco-Innovations (OTCQB:ONNVF) a conclu un accord de services avec Redwood AI pour faire avancer le développement de sa technologie exclusive de composés Polynucleotide Kinase Phosphatase (PNKP). Cette collaboration vise à renforcer les capacités de développement pharmaceutique de l'entreprise grâce à des outils chimiques pilotés par l'intelligence artificielle.
Le partenariat exploitera l'expertise de Redwood AI en évaluation de synthèse, chimiométrie et prédiction de toxicité spécifique aux organes pour la technologie PNKP. Le composé propriétaire cible les tumeurs solides en augmentant leur sensibilité à la radiothérapie et aux chimiothérapies endommageant l'ADN. Cette collaboration stratégique est conçue pour soutenir la progression d'Onco vers les études First-in-Human en améliorant l'évolutivité, la sécurité et la précision de la découverte.
Onco-Innovations (OTCQB:ONNVF) hat eine Dienstleistungsvereinbarung mit Redwood AI geschlossen, um die Entwicklung seiner exklusiv lizenzierten Polynucleotide Kinase Phosphatase (PNKP) Verbindungstechnologie voranzutreiben. Die Zusammenarbeit zielt darauf ab, die Wirkstoffentwicklung des Unternehmens durch KI-gestützte Chemie-Tools zu verbessern.
Die Partnerschaft nutzt Redwood AIs Expertise in Syntheseevaluierung, Cheminformatik und organspezifischer Toxizitätsvorhersage für die PNKP-Technologie. Die proprietäre Verbindung zielt auf solide Tumore ab, indem sie die Empfindlichkeit gegenüber Strahlung und DNA-schädigenden Chemotherapien erhöht. Diese strategische Zusammenarbeit soll Oncos Fortschritt zu First-in-Human-Studien durch verbesserte Skalierbarkeit, Sicherheit und Entdeckungspräzision unterstützen.
- Partnership with AI-driven platform could accelerate drug development timeline and reduce costs
- Access to advanced tools for synthesis evaluation and toxicity prediction
- Technology targets multiple solid tumors with potential to enhance treatment effectiveness
- Strategic advancement toward First-in-Human studies
- Still in preclinical phase with no immediate revenue potential
- Success of AI implementation in drug development remains unproven
VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a services agreement with Redwood AI Inc. (Redwood AI). This collaboration marks continued advancement of Onco's mission to accelerate the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound (the "Technology") and to extend its proprietary knowledge through discovery. This proprietary compound aims to target a range of solid tumours by enhancing sensitivity to radiation and DNA-damaging chemotherapies, offering the potential to exploit specific genetic susceptibilities in cancer. Through this agreement with Redwood AI, Onco gains access to Redwood AI's AI-driven chemistry tools that have the potential to unlock critical efficiencies in drug development, thereby carrying the potential to reduce synthesis complexity, refine compound design, and expand the pipeline of viable analogs. This effort is aimed at reinforcing Onco's technical capabilities at a crucial preclinical phase, with the goal of improving scalability, safety, and discovery precision.
Under the scope of the agreement, Redwood AI will provide multi-pronged support across synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the Technology and its structural analogs. This includes independent reviews of third-party chemistry proposals and the use of Redwood's proprietary in-silico modelling tools. In simpler terms, these efforts are intended to deepen Onco's understanding of its Technology by supporting structure-based refinement and mechanistic insight. These efforts are part of Onco's broader strategy to efficiently progress toward First-in-Human studies.
Redwood AI is a Vancouver-based artificial intelligence company harnessing artificial intelligence to accelerate drug synthesis and development. Founded by a team with deep roots in chemistry, AI, and drug manufacturing, including origins from Stanford1, Redwood AI is focused on overcoming one of the pharmaceutical industry's most persistent challenges - drug synthesis. By automating a substantial portion of the traditionally manual steps involved in synthesis, Redwood's technology aims to support more accurate, scalable, and cost-effective drug creation, with the goal of helping research teams move from discovery to development faster and with greater efficiency.
"The pace of innovation in cancer therapeutics depends on how quickly we can turn complex data into actionable decisions. Redwood AI's platform has the potential to enable us to explore synthesis strategies, evaluate risks, and optimize compound design with greater speed and precision. This kind of insight not only strengthens our scientific direction but also has the potential to accelerate our timeline towards clinical trials," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What is the partnership between Onco-Innovations (ONNVF) and Redwood AI?
How does Onco-Innovations' PNKP compound technology work?
What are the main benefits of the Redwood AI partnership for ONNVF?
What is the current development stage of Onco-Innovations' PNKP technology?
How will Redwood AI's technology benefit Onco-Innovations' drug development process?
